Sacubitrilat
Hypertensive Disorder
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06236061CT.gov Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy | — | Completed | — | — | — |
NCT01631864CT.gov Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypertensive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sacubitrilat (this asset) | Novartis Pharmaceuticals | P3 | BB · 64 |
| Hydrochlorothiazide | University of Kansas Medical Center | P4 | BBB |
| Valsartan | University of Alabama at Birmingham | P4 | BBB |
| Amlodipine | Jing Liu | P4 | BBB |
| Losartan | Rong Zhang | P4 | BBB |
| Olmesartan Medoxomil | Virginia Polytechnic Institute and State University | P4 | BBB |
| Trandolapril | University of Florida | P4 | BBB |
| Corpril | University of Michigan | P4 | BBB |
| Verapamil Slow Release | Abbott | P4 | BBB |
+42 more in the Hypertensive Disorder cohort
Other indications for Sacubitrilat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | BB · 65 |
| Essential Hypertension | — | P4 | BB · 65 |
| Neoplasm | — | P1/2 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Sacubitrilat in Hypertensive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/sacubitrilat-hypertensive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →